Courtesy of Canada Newswire & Sanofi
Toronto
Sanofi opened a 20,000-sf biomanufacturing center in May of 2024 in Toronto. Producing adult and pediatric vaccines for pertussis, diphtheria, and tetanus, the project significantly increases capacity to meet growing demand in Canada and around the world. The next-generation facility features advanced bioprocessing suites supported by highly efficient infrastructure. Commissioning is currently under way, with full operations slated to commence in mid-2025.
Sanofi is also constructing an influenza vaccine and pandemic preparedness hub on its Toronto campus. Representing over $800 million in support from the federal, provincial, and municipal governments, the end-to-end facility will open in 2027.
Source
